A comparative safety study of reported neurological adverse events with three COVID-19 vaccines

Review Health Care Sciences & Services

Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review

Martina Amanzio et al.

Summary: This systematic review compared the rates of adverse events (AEs) in the active and placebo groups of approved SARS-CoV-2 vaccines. The results showed that the occurrence of AEs was higher in the vaccine groups, and the most frequently reported AEs were fatigue, headache, local pain, and myalgia. These AEs were more common in the younger population and in the first dose of placebo recipients.

LANCET REGIONAL HEALTH-EUROPE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection

Martina Patone et al.

Summary: Emerging reports of rare neurological complications associated with COVID-19 infection and vaccinations are leading to concerns in regulatory, clinical, and public health sectors. A self-controlled case series study in England showed an increased risk of rare neurological complications following COVID-19 vaccination and infection. The study highlighted a higher risk of Guillain-Barre syndrome after ChAdOx1nCoV-19 vaccination.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Anton Pottegard et al.

Summary: This study assessed rates of cardiovascular and haemostatic events in Denmark and Norway after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S, finding increased rates of venous thromboembolic events among recipients. Despite slightly higher rates of thrombocytopenia/coagulation disorders and bleeding, the overall safety outcomes were largely reassuring.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Clinical Neurology

Guillain-Barre Syndrome following ChAdOx1-S/nCoV-19 Vaccine

Boby Maramattom et al.

Summary: In three districts of Kerala, India, around 1.5 million individuals have been vaccinated with COVID-19 vaccines, with over 80% receiving the ChAdOx1-S/nCoV-19 vaccine. Seven cases of Guillain-Barre syndrome (GBS) have been observed within this vaccinated population, with a frequency 1.4- to 10-fold higher than expected.

ANNALS OF NEUROLOGY (2021)

添加到收藏夹

Letter Clinical Neurology

Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia

Talal Al-Mayhani et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Noam Barda et al.

Summary: The study found that after receiving the BNT162b2 vaccine, most adverse events were not associated with an increased risk, although there was a slight increase in the risk of myocarditis. On the other hand, infection with the Covid-19 virus significantly increased the risk of many serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

A comparative safety study of reported neurological adverse events with three COVID-19 vaccines

相关参考文献

Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review

Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Guillain-Barre Syndrome following ChAdOx1-S/nCoV-19 Vaccine

Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

导出引文

分享论文